Nanomedicine: Not a case of “One size fits all”
Source abstract
Abstract
Summary Nanomedicine offers many benefits for the future treatment of disease conditions. The development of a nanomedicine may take different approaches but considerations of the disease, clinical practice, patient compliance and risk/benefit profiles are key to selecting the appropriate technologies.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (15)
Show source-provided references
1. Jiang · Expert Opin. Drug Del. · 2007 · 4 · 62110.1517/17425247.4.6.621 ↗
2. Park · J. Control. Rel. · 2007 · 120 · 110.1016/j.jconrel.2007.05.003 ↗
3. Mitropoulos · J. Colloid Interf. Sci. · 2008 · 317 · 64310.1016/j.jcis.2007.10.001 ↗
4. Nazarov · Pharm. Chem. J. · 2009 · 43 · 16310.1007/s11094-009-0259-2 ↗
5. Tevaarwerk · Clin. Cancer Res. · 2009 · 15 · 146010.1158/1078-0432.CCR-08-1599 ↗
6. Kesisoglou · Adv. Drug Del. Rev. · 2007 · 59 · 63110.1016/j.addr.2007.05.003 ↗
7. Mauludin · Eur. J. Pharm. Sci. · 2009 · 36 · 50210.1016/j.ejps.2008.12.002 ↗
8. Farokhzad · ACS Nano · 2009 · 3 · 1610.1021/nn900002m ↗
9. Owen · Pharmacogenet. Genom. · 2006 · 16 · 69310.1097/01.fpc.0000236338.41799.57 ↗
10. UNAIDS, Report on the Global AIDS Epidemic, 2008.
11. Zhang · Nat. Nanotechnol. · 2008 · 3 · 50610.1038/nnano.2008.188 ↗
12. www.mhra.gov.uk/Safetyinformation.
13. http://ec.europa.eu/health.
14. www.emea.europa.eu.
15. www.fda.gov/nanotechnology.